Lipid Nanoparticles for the Posterior Eye Segment
Open accessThe DOI matches its Crossref record; 161 of the 161 references it cites were found in a registry or an index.
Abstract
This review highlights the application of lipid nanoparticles (Solid Lipid Nanoparticles, Nanostructured Lipid Carriers, or Lipid Drug Conjugates) as effective drug carriers for pathologies affecting the posterior ocular segment. Eye anatomy and the most relevant diseases affecting the posterior segment will be summarized. Moreover, preparation methods and different types and subtypes of lipid nanoparticles will also be reviewed. Lipid nanoparticles used as carriers to deliver drugs to the posterior eye segment as well as their administration routes, pharmaceutical forms and ocular distribution will be discussed emphasizing the different targeting strategies most recently employed for ocular drug delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Barriers to ocular drug penetration: (a) the tear film is composed of three layers, the lipid layer, the aqueous layer and the mucin layer; (b) the corneal layer is formed by epithelium, Bowman’s membrane, stroma, Descemet’s membrane and endothelium; (c) the conjunctival barrier is vascularized; (d) the blood–aqueous barrier starts on the stroma of ciliary body and is composed by the basement membrane, pigmented cells, nonpigmented cells and delimited by the basement membrane; (e) the blood–retinal barrier is formed by the retinal ganglion cells, amacrine cells, bipolar cells, horizontal cells, both types of photoreceptors, retinal pigment epithelium (RPE) and the Bowman’s membrane. Adapted from [3,14,15], Sánchez-López, E., 2017; Farid, R.M., 2017; and Keeling, E., 2018.](https://figures.cochat.ai/paper-figures/81f1ec683a194953bac4868af7024759/lipid-nanoparticles-for-the-posterior-eye-segment-figure-1.jpg)
![Figure 2 Anatomy of the posterior segment of the eye. Adapted from [24,25] Akbar, S., 2017 and Bharali, P., 2015.](https://figures.cochat.ai/paper-figures/aaa59bfb5f1b44a89d521436564b298e/lipid-nanoparticles-for-the-posterior-eye-segment-figure-2.jpg)
![Figure 3 Representation of the different delivery routes for ocular administration [31,32]. Next to each administration, needle and injection technique are summarized. Adapted from [23,33,34,35,36,37,38,39], Varela-Fernandez, R., 2020; Doshi, R., 2011; Moshfeghi, D.M., 2002; Yïu, G., 2020; El Raves, E.N., 2013; Do, J.L., 2020; Pakravan, M., 2017; Davis, J.L., 2019.](https://figures.cochat.ai/paper-figures/b061b71884594be8a35a218a7f68fbc2/lipid-nanoparticles-for-the-posterior-eye-segment-figure-3.jpg)
![Figure 4 Three models of SLN drug incorporation: (a) homogeneous matrix model, (b) drug-enriched shell model, (c) drug enriched core model. Red color indicates the active compound encapsulated, yellow and grey color refer to lipid phases with and without dispersed drug, respectively. Adapted from [63], Müller, R. H., 2000.](https://figures.cochat.ai/paper-figures/8d1e7d9c9f08433cac2cdbb6456e23bb/lipid-nanoparticles-for-the-posterior-eye-segment-figure-4.jpg)
![Figure 5 Representation of the drug expulsion during storage of SLNs and three types of NLC: type-I structurally different lipids, type-II amorphous lipids and type-III liquid lipid included in solid matrix. Red color indicates the active compound. Adapted from [68,69], Müller, R.H., 2002; Narvekar, M., 2014.](https://figures.cochat.ai/paper-figures/7098428b8be3480c93c3636cfea6b382/lipid-nanoparticles-for-the-posterior-eye-segment-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, lipid-based transfection systems have shown success in their ability to transfer the target genes into retinal cells in several studies, and multiple lipid-based drugs for eye diseases are already available in the clinic35,79,87–91 and for the delivery of CRISPR or ribonucleoproteins for base editing.92,93”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [88]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Zhu, Y., & Sheng, Y. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119688 · Cited by 38
RetractedLiu, Z., Jiao, Z., Luo, R., & Fu, J. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102731 · Cited by 12
RetractedDanaei, M., Dehghankhold, M., Ataei, S., Hasanzadeh Davarani, F., Javanmard, R., Dokhani, A., Khorasani, S., & Mozafari, M. R. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10020057 · Cited by 4,832
Solid lipid nanoparticles (SLN) for controlled drug delivery â a review of the state of the art
Müller, R. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00087-4 · Cited by 3,759 · cited 6×
“The preemulsion is placed into ice-water bath and ultrasonicated using probe sonicator [63,70,71].”
BackgroundMethodInfluentialSolid lipid nanoparticles Production, characterization and applications
Mehnert, W. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00105-3 · Cited by 3,150 · cited 5×
“The drug is melted with the lipids and then dispersed in a hot aqueous phase with surfactants by a high-shear mixing device [56,71].”
BackgroundMethodInfluentialMüller, R. H., Radtke, M., & Wissing, S. A. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00118-7 · Cited by 2,113 · cited 6×
“This model is mainly obtained by high pressure homogenization due to the fact that the drug is dissolved in the bulk lipid and, through mechanical breaking, leads to nanoparticles with homogeneous matrix structure [66].”
BackgroundMethodInfluentialAge-related macular degeneration
Mitchell, P., Liew, G., Gopinath, B., & Wong, T. Y. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31550-2 · Cited by 1,511
Nanostructured lipid matrices for improved microencapsulation of drugs
Müller, R. H., Radtke, M., & Wissing, S. A. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00180-1 · Cited by 1,226
Design of liposomes as drug delivery system for therapeutic applications
Guimarães, D., Cavaco-Paulo, A., & Nogueira, E. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120571 · Cited by 1,196 · cited 1×
“Liposomes are able to enhance the active corneal permeability because of their ability to come in close contact with cornea and conjunctiva as well as increase the extent of corneal uptake by prolonging the corneal contact time [54,55].”
BackgroundThe progress in understanding and treatment of diabetic retinopathy
Stitt, A. W., Curtis, T. M., Chen, M., Medina, R. J., McKay, G. J., Jenkins, A., Gardiner, T. A., Lyons, T. J., Hammes, H.-P., Simó, R., et al. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.08.001 · Cited by 1,164
Research works printed but not linked: 2
- Patel, J.K., Sutariya, V., Kanwar, J.R., Pathak, Y.V., Eds.; Springer International Publishing: Cham, Switzerland, 2018; pp. 3-33. [CrossRef]
- Pawan, S.; Navneet, V. A review on impact of nanomicelle for ocular drug delivery system. Int. J. Pharm. Sci. Res. 2018, 9, 1397-1404.
Cited by
Akbari, J., Saeedi, M., Ahmadi, F., Hashemi, S. M. H., Babaei, A., Yaddollahi, S., Rostamkalaei, S. S., Asare-Addo, K., & Nokhodchi, A. (2022) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2022.2084554 · Cited by 181
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Recent Developments of Nanostructures for the Ocular Delivery of Natural Compounds
Razavi, M. S., Ebrahimnejad, P., Fatahi, Y., D’Emanuele, A., & Dinarvand, R. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.850757 · Cited by 92
“The negatively charged epithelium provides an opportunity for cationic SLN particles to enhance the drug retention time on the eye and increase its absorption (Bonilla et al., 2022).”
BackgroundsiRNA Functionalized Lipid Nanoparticles (LNPs) in Management of Diseases
Kalita, T., Dezfouli, S. A., Pandey, L. M., & Uludağ, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112520 · Cited by 99
Wu, Y., Li, X., Fu, X., Huang, X., Zhang, S., Zhao, N., Ma, X., Saiding, Q., Yang, M., Tao, W., et al. (2024) · Advanced Science · doi:10.1002/advs.202403399 · Cited by 106
Qi, Q., Wei, Y., Zhang, X., Guan, J., & Mao, S. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.055 · Cited by 79
Afarid, M., Mahmoodi, S., & Baghban, R. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01567-7 · Cited by 76
“amacrine cells, and the retinal ganglion cells [26]”
BackgroundInfluentialLi, W., Chen, L., Gu, Z., Chen, Z., Li, H., Cheng, Z., Li, H., & Zou, L. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.080 · Cited by 61
Lipid-based nanoparticles: innovations in ocular drug delivery
Baig, M. S., Karade, S. K., Ahmad, A., Khan, M. A., Haque, A., Webster, T. J., Faiyazuddin, M., & Al-Qahtani, N. H. S. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1421959 · Cited by 65
Fathi, F., Machado, T. D. O. X., Kodel, H. D. A. C., Portugal, I., Ferreira, I. O., Zielińska, A., Oliveira, M. B. P. P., & Souto, E. B. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2410951 · Cited by 46
“…compounds for treating various human disorders, including lung and oral cancer [1,2], brain tumors [3], eye diseases (e.g. glaucoma, diabetic retinopathy, age-related macular degeneration) [4,5], skin disorders [6,7], and neurodegenerative diseases (e.g. Alzheimer’s and Parkinson’s) [8,9].”
Self-citationAdvancing Medicine with Lipid-Based Nanosystems—The Successful Case of Liposomes
Luiz, H., Pinho, J. O., & Gaspar, M. M. (2023) · Biomedicines · doi:10.3390/biomedicines11020435 · Cited by 50
“Furthermore, in a phase I/II clinical trial (NCT02006147), a liposome ophthalmic formulation of dexamethasone sodium phosphate (TLC399) effectively improved macular edema secondary to retinal vein occlusion [72,80].”
BackgroundDually Active Apigenin-Loaded Nanostructured Lipid Carriers for Cancer Treatment
Bonilla-Vidal, L., Świtalska, M., Espina, M., Wietrzyk, J., García, M. L., Souto, E. B., Gliszczyńska, A., & Sánchez‐López, E. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s429565 · Cited by 38
Self-citationNanostructure-Mediated Transport of Therapeutics through Epithelial Barriers
Hansen, M. E., Ibrahim, Y., Desai, T. A., & Koval, M. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137098 · Cited by 34
Faria, M. J., González‐Méijome, J. M., Oliveira, M. E. C. D. R., Carracedo, G., & Lúcio, M. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115321 · Cited by 31
Supe, S., Upadhya, A., Tripathi, S. D., Dighe, V. D., & Singh, K. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01281-9 · Cited by 34
Liu, X., Huang, K., Zhang, F., Huang, G., Wang, L., Wu, G., Ren, H., Yang, G., & Lin, Z. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02614-1 · Cited by 30
“Drugs can be transported through both transcellular and paracellular pathways [58].”
BackgroundNovel nanostructured lipid carriers loading Apigenin for anterior segment ocular pathologies
Bonilla-Vidal, L., Espina, M., García, M. L., Baldomà, L., Badı́a, J., Sánchez, J. A. G., Delgado, L. M., Gliszczyńska, A., Souto, E. B., & Sánchez‐López, E. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124222 · Cited by 24
Self-citationCimino, C., López, E. S., Bonaccorso, A., Bonilla-Vidal, L., Musumeci, T., Badía, J., Baldomà, L., Pignatello, R., Marrazzo, A., Barbaraci, C., et al. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124300 · Cited by 24
Self-citationLong-acting formulation strategies for protein and peptide delivery in the treatment of PSED
Garkal, A., Bangar, P., Rajput, A., Pingale, P., Dhas, N. L., Sami, A., Mathur, K., Joshi, S., Dhuri, S., Parikh, D. C., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.08.040 · Cited by 24
Breaking Barriers: Nanomedicine-Based Drug Delivery for Cataract Treatment
Chen, Y., Ye, Z., Chen, H., & Li, Z. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s463679 · Cited by 28
“92,93 To overcome the stability issues of SLNs, NLCs were developed, featuring a matrix comprising both solid and liquid lipids.”
Zhang, Y., Watson, S. L., Ramaswamy, Y., & Singh, G. (2024) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2024.103200 · Cited by 28
Kąpa, M., Koryciarz, I., Kustosik, N., Jurowski, P., & Pniakowska, Z. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030683 · Cited by 25
Nanomaterials in the diagnosis and treatment of ophthalmic diseases
Ma, Y., Zhang, Z., Yu, Y., Wang, X., Liu, S., Sun, B., Cai, Z., Cui, W., Zhou, X., & Zhao, J. (2024) · Nano Today · doi:10.1016/j.nantod.2023.102117 · Cited by 25
Lipid nanoparticle technology-mediated therapeutic gene manipulation in the eyes
Wang, T., Yu, T., Liu, Q., Sung, T., & Higuchi, A. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102236 · Cited by 22
Diclofenac Loaded Biodegradable Nanoparticles as Antitumoral and Antiangiogenic Therapy
Esteruelas, G., Souto, E. B., Espina, M., García, M. L., Świtalska, M., Wietrzyk, J., Gliszczyńska, A., & Sánchez‐López, E. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010102 · Cited by 19
“Moreover, since Lutrol is a non-ionic s rfactant used as an emulsifier, it is also important to determine the optimal c centration [21,42,43].”
BackgroundSelf-citationGonzález‐Fernández, F. M., Delledonne, A., Nicoli, S., Gasco, P., Padula, C., Santi, P., Sissa, C., & Pescina, S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020407 · Cited by 19
Peng, X., Zhang, T., Liu, R., & Jin, X. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04798-w · Cited by 18
Precision Medicines for Retinal Lipid Metabolism-Related Pathologies
da Ana, R., Gliszczyńska, A., Sánchez‐López, E., García, M. L., Krambeck, K., Kovačević, A. B., & Souto, E. B. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13040635 · Cited by 24
Self-citationFlurbiprofen loaded thermosensitive nanohydrogel for ophthalmic anti-inflammatory therapy
Wu, B., Feng, J., Zeng, T., Guo, Q., Zhang, Z., Ding, C., Tian, B., & Sai, S. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103253 · Cited by 16
Sharma, Y., Patel, P., & Kurmi, B. D. (2023) · Current Drug Delivery · doi:10.2174/1567201820666230504115446 · Cited by 18
Nanotechnology-based advancements for effective delivery of phytoconstituents for Ocular diseases
Krishnaswami, V., Mohanan, D. P., Raja, S. A. J., Natarajan, B., & Velusamy, S. (2024) · Nano TransMed · doi:10.1016/j.ntm.2024.100056 · Cited by 16
Cannabinoid-Based Ocular Therapies and Formulations
Saraiva, S. M., Martín‐Banderas, L., & Durán‐Lobato, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041077 · Cited by 15
“Proteins, lipids, as well as polymers derived from natural and synthetic sources, namely chitosan, albumin, sodium alginate, polylactic acid (PLA), poly-lactic-co-glycolic acid (PLGA) or polycaprolactone (PCL), lecithin, phosphatidylcholine, oleic acid, vitamin E and medium-chain triglycerides (MCT), among others, hav…”
BackgroundCimino, C., Leotta, C. G., Marrazzo, A., Musumeci, T., Pitari, G. M., Pignatello, R., Bonaccorso, A., Amata, E., Barbaraci, C., & Carbone, C. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104811 · Cited by 11
Melatonin loaded nanostructured lipid carriers for the treatment of uveal melanoma
Bonilla-Vidal, L., Espina, M., García, M. L., Cimino, C., Carbone, C., Baldomà, L., Badı́a, J., Gliszczyńska, A., Souto, E. B., & Sánchez‐López, E. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106057 · Cited by 10
“By incorporating liquid lipids into the formulation, NLC enhanced the cargo capacity of NP and improved storage stability [14 – 16].”
InfluentialSelf-citationBondok, M., Nguyen, A. X.-L., Landó, L., & Wu, A. Y. (2024) · Clinical ophthalmology · doi:10.2147/opth.s501494 · Cited by 12
Antitumoral melatonin-loaded nanostructured lipid carriers
Bonilla-Vidal, L., Świtalska, M., Espina, M., Wietrzyk, J., García, M. L., Souto, E. B., Gliszczyńska, A., & Sánchez‐López, E. (2024) · Nanomedicine · doi:10.1080/17435889.2024.2379757 · Cited by 10
Self-citationAn overview of ocular drug delivery systems—conventional and novel drug delivery systems
Virmani, T., Kumar, G., Sharma, A., & Pathak, K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15264-1.00007-5 · Cited by 13
Cimino, C., Bonilla-Vidal, L., Conti, F., Sánchez‐López, E., Bucolo, C., García, M. L., Musumeci, T., Pignatello, R., & Carbone, C. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00725 · Cited by 10
Self-citationLipid nanoparticles in antiretroviral therapy: A nanotechnology breakthrough for HIV/AIDS treatment
Suriyarachchi, D. D. C., & Katuwavila, N. P. (2025) · HIV Medicine · doi:10.1111/hiv.13770 · Cited by 10
“…Sufficient pharmacokinetic features [76] Formulation and most of the reported studies were just in vitro valuation [19] Inhibits ocular toxicity [77] Lipid nanoparticles toxicity on retinal cells have not been extensively studied [21] Good stability and biocompatibility [23] Parenteral Lower…”
Velasco, S., Gallego, I., Olivares‐González, L., Puras, G., Castro, M. C., Salom, D., Pedraz, J. L., & Rodrigo, R. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117962 · Cited by 9
A Nanogel Formulation of Anti-VEGF Peptide for Ocular Neovascularization Treatment
Durak, S., Sutova, H. E., Ceylan, R., Açıksarı, A., Yetisgin, A. A., Tokuç, E. Ö., Kutlu, Ö., Karabas, V. L., & Çetinel, S. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.4c00585 · Cited by 11
Bonilla-Vidal, L., Espina, M., García, M. L., Baldomà, L., Badía, J., Gliszczyńska, A., Souto, E. B., & Sánchez‐López, E. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.125160 · Cited by 8
Self-citationLocalization of fluorescent gold nanoparticles throughout the eye after topical administration
Raîche-Marcoux, G., Méthot, S. J., Tchatchouang, A., Bettoli, C., Maranda, C., Loiseau, A., Proulx, S., Rochette, P. J., Génin, E., & Boisselier, É. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1557611 · Cited by 9
Current state and potential of polymersomes as ocular drug delivery systems
Yetisgin, A. A., Sivakumar, P. M., & Çetinel, S. (2025) · Nanoscale · doi:10.1039/d5nr01273b · Cited by 12
Cimino, C., Zingale, E., Bonaccorso, A., Musumeci, T., Carbone, C., & Pignatello, R. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00554 · Cited by 7
Recent Achievements and Perspectives in Smart Nano-in-Micro Platforms for Ocular Disease Treatment
Huang, Y., Yan, D., Ouyang, W., Hu, J., & Liu, Z. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s518643 · Cited by 7
Bonilla-Vidal, L., Świtalska, M., Espina, M., Wietrzyk, J., García, M. L., Souto, E. B., Gliszczyńska, A., & Sánchez‐López, E. (2024) · Materials & Design · doi:10.1016/j.matdes.2024.113573 · Cited by 7
Self-citationBao, L., Qiao, F., Yu, N. H., Zhao, Q., Zuo, W., & Yang, J. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.143028 · Cited by 6
Singh, A. K., Kumar, M., & Upadhyay, P. K. (2023) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201025666230907145019 · Cited by 6
Yetisgin, A. A., Durak, S., Kutlu, Ö., & Çetinel, S. (2024) · Macromolecular Bioscience · doi:10.1002/mabi.202300531 · Cited by 6
Johari, M., Baghban, R., Salari, R., & Attar, A. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118911 · Cited by 5
Approaches for designing and delivering solid lipid nanoparticles of distinct antitubercular drugs
Vasam, M., & Goulikar, R. K. (2022) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2022.2144791 · Cited by 5
“This sort of SLNPs provides a quick release [22].”
BackgroundBreaking the ocular barrier through nano-lipid carriers to treat intraocular diseases
Giri, S., Badwaik, H. R., & Giri, T. K. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104867 · Cited by 5
Chemically modified hyaluronic acid derivatives as ocular drug carriers: A review
Sen, O., De, S., Dey, G., Das, S., Bhowmik, M., Jana, S., Nandi, G., & Manna, S. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145049 · Cited by 5
Kumari, G., Kundu, S., Famta, P., Kalahasti, K. K., Srivastava, S., Reddy, G. B., & Srinivasarao, D. A. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01971-0 · Cited by 4
“Furthermore, a few lipophilic drugs also get permeated through the sclera and can reach the posterior tissues through lateral scleral diffusion (whereupon these molecules pass through Bruch’s membrane and the RPE) [ 57].”
Nanomedicine for Ocular Drug Delivery
Xu, X., & Zuo, Y. Y. (2022) · Micro/Nano technologies · doi:10.1007/978-981-13-9374-7_32-1 · Cited by 3
Nanomedicine for Ocular Drug Delivery
Xu, X., & Zuo, Y. Y. (2023) · Micro/Nano technologies · doi:10.1007/978-981-16-8984-0_32 · Cited by 4
The role of blood–brain and blood–retinal barriers in drug delivery
Bonilla-Vidal, L., Esteruelas, G., Souto, E. B., Espina, M., García, M. L., & López, E. S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90471-1.00002-5 · Cited by 3
Self-citationHou, X.-Y., Zhang, X.-L., Ying, A., Yue, Y., Yang, T., Guo, D., & Li, Z. (2025) · Drug Delivery · doi:10.1080/10717544.2025.2509962 · Cited by 4
“…via the corneal pathway, lateral diffusion across the sclera, and the penetration of Bruch’s membrane to reach the retinal pigment epithelium (Bonilla et al. 2021). in this context, it has been hypothesized that scleral absorption is the main pathway because of the absence of fluorescence…”
Wang, E., Feng, B., Chen, S., Wang, H., Ling, T., & Chakrabarti, S. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.1.24 · Cited by 2
“41,42 In the present study, we found that daily topical administration of GalNAc-modified siHOTAIR was equally as effective as weekly intravitreal injections, suggesting that topical GalNAc-modified siHOTAIR could be a viable treatment for HOTAIR-associated dysfunction in DR. GalNAc-modified…”
Durak, S., Yetisgin, A. A., Açıksarı, A., Ceylan, R., Tokuç, E. Ö., Kutlu, Ö., Karabas, V. L., & Çetinel, S. (2026) · Macromolecular Bioscience · doi:10.1002/mabi.202500263 · Cited by 2
“The polydispersity index (PDI) results less than 0.3 indicate monodis-perse particles with narrow particle distribution [ 43 ].”
InfluentialYetisgin, A. A., Kutlu, Ö., & Çetinel, S. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107156 · Cited by 2
Zhang, L., Wang, J., Yu, J.-M., Zou, L., & Sheng, F. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.157806 · Cited by 3
Nucleic acid drug delivery in ophthalmology: Emerging trends and future perspectives
Yang, H., Zuo, J., Lv, S., Wei, X., Pan, M., Zhu, Z., Wang, Y., Jie, Y., Lu, Z., & Zhang, X. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114729 · Cited by 1
Nanocarrier-Based Ocular Drug Delivery Systems for Retinal Diseases: Therapeutic Potential
Skarbek, D., Sochocka, A., Sidło, O., Sapiaszko, A., Drab, A., Baj, J., Ręjdak, R., & Dolar-Szczasny, J. (2026) · Life · doi:10.3390/life16050810 · Cited by 1
“These barriers significantly hinder the development of effective therapeutic strategies [3,10].”
InfluentialPolymeric and lipid nanocarriers in glaucoma
Lalan, M. S., Shah, P., Barve, K. H., Jha, R., & Jha, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15264-1.00013-0 · Cited by 1
Nanotechnological Drug Delivery Strategies in Epilepsy
Esteruelas, G., Bonilla-Vidal, L., Ettcheto, M., Haro, I., Gomara, M. J., Souto, E. B., Espina, M., Camins, A., García, M. L., Sánchez‐López, E., et al. (2023) · Springer eBooks · doi:10.1007/978-981-99-6807-7_14 · Cited by 1
Self-citationDrug Delivery to the Posterior Segment of Eye
Tarannum, S., & Jain, K. (2025) · Springer eBooks · doi:10.1007/978-981-96-6306-4_4 · Cited by 2
Bonilla-Vidal, L., Esteruelas, G., Ettcheto, M., Gomara, M. J., Haro, I., Souto, E. B., Espina, M., Camins, A., García, M. L., Cano, A. C., et al. (2023) · Springer eBooks · doi:10.1007/978-981-99-6807-7_18
Self-citationSafety assessment and toxicological considerations of nanocarriers in ophthalmic drug delivery
Manchanda, N., Kaul, S., Mittal, S., & Talegaonkar, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33781-9.00017-4
Goyal, S., & Vanita, V. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43986-5.00042-4
Paganini, V., da Ana, R., Neto, J. G. D. O., Neto, O. C. D. S., dos Santos, A. O., de Sousa, F. F., Chetoni, P., & Souto, E. B. (2026) · ChemistrySelect · doi:10.1002/slct.73812
Self-citationGoyal, S., Ankur, Garima, G., Swami, R., & Mittal, N. (2026) · AAPS PharmSciTech · doi:10.1208/s12249-026-03538-9
“Furthermore, the Korsmeyer–Peppas model suggested a non-Fickian (anomalous) transport mechanism, where drug release occurs through a combination of diffusion and matrix relaxation [49].”
Engineering and optimization of microfluidic platforms for phospholipid-based ocular drug delivery
Kankanamlage, S. D., Thrimawithana, T. R., & Tovar-Lopez, F. J. (2026) · Journal of Liposome Research · doi:10.1080/08982104.2026.2740639
Advancing nanomaterials for treatment of eye diseases: a review
Amiryaghoubi, N., Sadeghi, M., Sadeghi, F., Amirsaadat, S., Jaymand, M., Akbari, M., Liu, G., & Jahanban, R. (2026) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2026.105087
Metadata
- Authors
- Bonilla, L., Espina, M., Severino, P., Cano, A., Ettcheto, M., Camins, A., García, M. L., Souto, E. B., & Sánchez-López, E.
- Affiliations
- Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain
- Institut de Nanociència i Nanotecnologia de la Universitat de Barcelona (ES)
- Industrial Biotechnology Program, University of Tiradentes (UNIT), Av. Murilo Dantas 300, Aracaju 49032-490, Brazil
- Biomedical Research Networking Center on Neurodegenerative Diseases (ES)
- University of Minho (PT)
- Corresponding author
- Souto, Eliana B.
- ORCID
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2021-12-31
- Volume
- 14
- Issue
- 1
- Pages
- 90
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC8779178
- OpenAlex
- W4205965704
- Cited by
- 76
- References
- 160
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 22 · 2023: 20 · 2022: 10
- FWCI
- 1.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by-nc-nd)
- Funders
- Fundação para a Ciência e a Tecnologia (UIDB/04469/2020, COMPETE, PT2020, UIDB/04469)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Keywords
- lipid nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, lipid-drug conjugates, ocular drug delivery, ocular distribution, eye anatomy, posterior segment diseases, nanoparticle synthesis, route of administration
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.